ACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO
|
|
- Muriel McGee
- 5 years ago
- Views:
Transcription
1 ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO
2 Disclosure of Commercial Interest Dr. Badesch has received grant/research support from Glaxo Wellcome, United Therapeutics / Lung Rx, Actelion, Encysive, Myogen/Gilead, CoTherix/Actelion, Pfizer, and Lilly/ICOS. He has served as a consultant to Glaxo Wellcome / GlaxoSmithKline, Actelion, Berlex, Myogen/Gilead, Encysive, CoTherix/Actelion, Pfizer, United Therapeutics, MondoBiotech/Biogen IDEC, and PR Pharmaceuticals.
3 Symptomatic Pulmonary Arterial Hypertension ACCP 2007 General Treatment Measures: Oral anticoagulants [B for IPAH, E/C for other PAH] + diuretics + oxygen [E/A] Acute Vasoreactivity Testing [A for IPAH, E/C for other PAH] Positive Negative Oral CCB [B for IPAH, E/B for other PAH] FC II FC III FC IV Sustained Response? Yes No Continue CCB Sildenafil [A] Treprostinil SC [C] Treprostinil IV [C] Bosentan [A] Sildenafil [A] Epoprostenol [A] Iloprost inh [A] Treprostinil SC [B] Treprostinil IV [C] Epoprostenol IV [A] Bosentan [B] Iloprost inh [B] Sildenafil [C] Treprostinil SC [C] Treprostinil IV [C] Combination Therapy? Prostanoid Bosentan Sildenafil Grade of Recommendation Noted in [ ] Badesch, Abman, Simonneau,et al. Chest 131: ;131. No Improvement or deterioration Atrioseptostomy + Lung Transplantation
4 ACCP Guidelines Statement Quality of Evidence, Net Benefit, and Strength of Recommendation Quality of the Evidence Good: based on RCTs or metaanalyses. Fair: based on controlled trials or RCTs with minor flaws. Low: based on nonrandomized, case-control, or other observational studies. Expert opinion: no studies meet the criteria for inclusion in the literature review. Net Benefit: Substantial Intermediate Small/weak None Conflicting Negative Strength of Recommendation: A: Strong recommendation B: Moderate recommendation C: Weak recommendation D: Negative recommendation I: No recommendation possible E/A: Strong recommendation based on expert opinion only E/B: Moderate recommendation based on expert opinion only
5 ACCP Guidelines Statement Relationship of Strength of the Recommendation Scale to Quality of Evidence and Net Benefits Quality of Evidence Net Benefit Substantial Intermediate Small/Weak None Conflicting Negative Good A A B D I D Fair A B C D I D Low B C C I I D Expert Opinion E/A E/B E/C I I E/D
6 Determining Pulmonary Vasodilator Reserve Establish the role of vasoconstriction Determine the potential for vasodilator therapy Should be measured in most patients prior to initiating treatment
7 ACCP Consensus Definition of A Responder Fall in mean PAP by at least 10 mm Hg, to an absolute PAP mean of < mm Hg Unchanged or increased CO It is important to follow patients treated with CCBs for both safety and efficacy of the therapy. ACCP=American College of Chest Physicians.
8 Medical Therapy: Vasoreactivity Testing 1. Patients with IPAH should undergo acute vasoreactivity testing using a short acting agent such as intravenous epoprostenol, adenosine, or inhaled nitric oxide. Level of Evidence: Fair; Benefit: Substantial; Grade of Recommendation: A. 2. Patients with PAH associated with underlying processes, such as scleroderma or congenital heart disease, should undergo acute vasoreactivity testing. Level of Evidence: Expert Opinion; Benefit: Small/Weak; Grade of Recommendation: E/C. 3. Patients with PAH should undergo vasoreactivity testing by a physician experienced in the management of pulmonary vascular disease. Level of Evidence: Expert Opinion; Benefit: Substantial; Grade of Recommendation: E/A.
9 Medical Therapy: Calcium Channel Blockers 4. Patients with IPAH, in the absence of right heart failure, demonstrating a favorable acute response to vasodilator (defined as a fall in mean pulmonary artery pressure of at least 10 mmhg to less than or equal to 40 mmhg, with an increase or unchanged cardiac output), should be considered candidates for a trial of therapy with an oral calcium channel antagonist. Level of Evidence: Low; Benefit: Substantial; Grade of Recommendation: B. 5. Patients with PAH associated with underlying processes such as scleroderma or congenital heart disease, in the absence of right heart failure, demonstrating a favorable acute response to vasodilator (defined as a fall in mean pulmonary artery pressure of at least 10 mmhg to less than or equal to 40 mmhg, with an increase or unchanged cardiac output), should be considered candidates for a trial of therapy with an oral calcium channel antagonist. Level of Evidence: Expert Opinion; Benefit: Intermediate; Grade of Recommendation: E/B.
10 Medical Therapy: Calcium Channel Blockers 6. In patients with PAH, calcium channel blockers should not be used empirically to treat pulmonary hypertension in the absence of demonstrated acute vasoreactivity. Level of Evidence: Expert Opinion; Benefit: Substantial; Grade of Recommendation: E/A.
11 ACCP 2007 Acute Vasoreactivity Testing [A for IPAH, E/C for other PAH] Positive Oral CCB [B for IPAH, E/B for other PAH] Sustained Response? Yes Continue CCB No Grade of Recommendation Noted in [ ] Badesch, Abman, Simonneau,et al. Chest 131: ;131.
12 Medical Therapy: Anticoagulation and Supplemental Oxygen 7. Patients with IPAH should be anticoagulated with warfarin. Level of evidence: Fair; Benefit: Intermediate; Grade of Recommendation: B. 8. In patients with PAH occurring in association with other underlying processes, such as scleroderma or congenital heart disease, anticoagulation should be considered. Level of Evidence: Expert opinion; Benefit: Small/Weak; Recommendation: E/C. 9. In patients with PAH, supplemental oxygen should be used as necessary to maintain oxygen saturations at > 90% at all times. Level of Evidence: Expert Opinion; Benefit: Substantial; Recommendation: E/A.
13 Symptomatic Pulmonary Arterial Hypertension ACCP 2007 General Treatment Measures: Oral anticoagulants [B for IPAH, E/C for other PAH] + diuretics + oxygen [E/A] Acute Vasoreactivity Testing [A for IPAH, E/C for other PAH] Positive Oral CCB [B for IPAH, E/B for other PAH] Sustained Response? Yes Continue CCB Grade of Recommendation Noted in [ ] Badesch, Abman, Simonneau,et al. Chest 131: ;131.
14 PAH: Advanced Therapy SMC A) PGI 2 EC PGI 2 -S Arach. a. PGI 2 camp PGI 2 Prostanoids Epoprostenol Treprostinil Beraprost Iloprost TxA 2 SMC PDE 5 cgmp Vasodilation Antiproliferative B) NO Vasoconstriction EC NO Proliferation L-arginine L-citrulline C) ET-1 SMC G I ET A ET B EC Pre-pro-ET pro-et ET-1 Adapted from Omar Manai.
15 Epoprostenol in PPH Study Median Change from Baseline in 6-Minute Walk Exercise Test at Week 12 Median Change (meters) *P< Treatment: Epoprostenol Baseline = 315 Conventional Baseline = 270 Barst RJ et al. NEJM 334: , 1996.
16 Cardiopulmonary Hemodynamic Measurements (PPH) Epoprostenol vs. Conventional Therapy Epoprostenol Conventional Change from Change from Variable Baseline Baseline Baseline Baseline PAP m 61 ± ± 1.3* 59 ± ± 1.6 PVR 16 ± ± 0.7* 16 ± ± 1.2 RAP m 13 ± ± 1.1* 12 ± ± 0.9 CI 2.0 ± ± 0.1* 2.1 ± ± 0.2 Mean change ± standard error *Significantly different from conventional therapy Barst RJ et al. NEJM 334: , 1996.
17 Survival Among Patients with PPH Epoprostenol vs. Conventional Therapy Survival (%) Epoprostenol (n = 41) Conventional therapy (n = 40) Week Barst et al. NEJM 1996;334:
18 Survival in PPH 100 % Survival * * * Observed Expected Months *p< McLaughlin VV et al. Circulation. 2002;106:
19 PAH Associated with Scleroderma: Median Change from Baseline in 6-Minute Walk Test Median Change (meters) Treatment: Week 1 Week 6 Week 12 Epoprostenol Baseline = 271.5m Badesch, et al. Ann Intern Med, 2000;132: * * *P< Conventional Baseline = 240.0m
20 PAH Associated with Scleroderma Cardiopulmonary Hemodynamic Measurements Epoprostenol Conventional Change from Change from Variable Baseline Baseline Baseline Baseline PAP m 50.9 ± ± 1.09* 49.1 ± ± 1.10 PVR 14.2 ± ± 0.76* 11.2 ± ± 0.56 RAP m 13.1 ± ± 0.82* 11.1 ± ± 0.69 CI 1.9 ± ± 0.08* 2.2 ± ± 0.08 Mean change ± standard error *Significantly different from conventional therapy Badesch,, et al. Ann Intern Med, 2000;132:
21 Treprostinil in PAH Exercise Capacity: Six Minute Walk Change from Baseline UT-15 Placebo Effect* p-value Exercise (meters) Week Week Week *Non-parametric Analysis of Covariance (Hodges-Lehmann estimate) Last Rank Carried Forward for AE Lowest Rank for Death/Deterioration Simonneau G et al. AJRCCM 165:800-4; 2002.
22 Treprostinil in PAH Change in Exercise Versus Dose(Week 12) Mean ± SE Change from Baseline (meters) Meters ± 10 (N=45) +1.4 ± 9 (N=55) +20 ± 8 (N=49) 1st 2nd 3rd Quartile < Quartile 5 Quartile 5.0 to < to ± 31 (N=58) 4th Quartile >13.8 (2.5 ± 0.2) (5.6 ± 0.1) (9.4 ± 0.2) (16.2 ± 0.4) mg/kg/min Simonneau G et al. AJRCCM 165:800-4; p-value 0.03
23 Chronic Inhaled Iloprost in PAH Effect of Inhaled Iloprost and Placebo on the Mean ({+/-}SE) Change from Base Line in the Distance Walked in Six Minutes, According to an Intention-to-Treat Analysis Olschewski, H. et al. N Engl J Med 2002;347:
24 PAH: Advanced Therapy SMC camp A) PGI 2 EC PGI 2 -S Arach. a. PGI 2 PGI 2 TxA 2 SMC PDE 5 cgmp Vasodilation Antiproliferative B) NO Vasoconstriction EC NO Proliferation L-arginine L-citrulline C) ET-1 Adapted from Omar Manai. SMC EC Pre-pro-ET pro-et G I ET A ET B ET-1 Bosentan Sitaxsentan Ambrisentan
25 Endothelin Met Leu Ser Ser Cys Ser Cys NH 2 Asp Lys Glu Cys Val Tyr Phe Cys His Leu Asp Ile Ile Trp CO 2 First identified in 1988; at the time, the most potent endogenous vasoconstrictor known Also has effects on inflammation, proliferation, and fibrosis. Present within the plexiform lesions of IPAH/PPH. (Giaid( Giaid A et al. New Engl J Med. 1993; 328:1732)
26 Pilot Study of Bosentan in PAH: 6-Minute Walk Test Change From Baseline Over Time 100 Placebo (n = 11) Bosentan (n = 21) P = 0.02 Meters Channick et al. Lancet 358: Weeks Primary Endpoint
27 Pilot Study of Bosentan in PH: Change in Hemodynamics From Baseline to Week 12 Cardiac Index Mean Pulmonary Arterial Pressure Pulmonary Vascular Resistance L/min/m P < Week 12 mm Hg P = Week 12 Dyn.sec.cm P = Week 12 Placebo (n = 10) Bosentan (n = 20) Channick et al. Lancet 358:
28 BREATHE-1: Walk Test ITT Change From Baseline to Week 16 Walk Distance (meters) 80 Placebo (n = 69) Bosentan (n = 144) P = Mean ± SEM -40 Baseline Week 4 Week 8 Week mg/bid 125 or 250 mg/bid Rubin et al. NEJM 346: l 2002.
29 Event-Free (%) BREATHE-1 Time to Clinical Worsening Up to 28 Weeks P = Time (weeks) 89 % 63 % Bosentan n = 144 n = 103 n = 20 Placebo n = 69 n = 51 n = 17 Rubin et al. NEJM 346: l 2002.
30 BREATHE-1 Summary of Adverse Events During Study Treatment Placebo Bosentan (n = 69) (n = 144) % % Nasopharyngitis Headache Flushing Hypotension Syncope Hepatic Funct.. Abnormal Incidence of events: bosentan > placebo Rubin et al. NEJM 346: l 2002.
31 Bosentan as Initial Therapy* Observed and Predicted Survival Kaplan-Meier survival estimates with 99.9% CI % of event-free patients Observed Predicted (NIH) Event Rate / year (exponential): 5.5% months Patients at risk McLaughlin V. Eur Respir J 25:244-9; 2005 *As first-line treatment for PPH. Some patients may have been switched to alternative therapies.
32 Sitaxsentan in PAH STRIDE 1: Six-Minute Walk Distance * * Placebo 100 mg 300 mg Meters Week 6 Week 12 *p<0.01; mean +/- SE. Barst RJ et al. Am J Respir Crit Care Med. 2004;169:
33 Sitaxsentan in PAH STRIDE 1: Change in Hemodynamics Placebo 100 mg 300 mg mpap (Mm Hg) CI (L/min/m 2 ) * ** PVR (dyn sec cm-5) * *p<0.001 vs placebo; Mean +/- SE *p<0.02 vs placebo; **p<0.001 vs placebo Barst RJ et al. Am J Respir Crit Care Med. 2004;169: * *p<0.001 vs placebo *
34 Sitaxsentan in PAH STRIDE 1 : Most Frequent Adverse Events Adverse Event Placebo n=59 (%) Sitaxsentan 100 mg n=56 (%) Sitaxsentan 300 mg n=63 (%) Headache 20 (34) 25 (45) 29 (46) Peripheral edema 10 (17) 9 (16) 16 (25) Nausea 11 (19) 13 (23) 11 (17) Increased INR 3 (5) 8 (14) 15 (24) Nasal congestion 6 (10) 9 (16) 13 (21) Dizziness 6 (10) 8 (14) 6 (10) Barst RJ et al. Am J Respir Crit Care Med. 2004;169:
35 Sitaxsentan in PAH STRIDE 1: LFT Results STRIDE 1/1x (Longer-term Exposure) % patients with LFT elevations >3x ULN (2/59) STRIDE-1 (12 weeks) (0/56) (6/63) Chronic Exposure (median 24 weeks; Mean ± SD: 26 ± 14 weeks; Range 1 day 58 weeks) (4/79) (19/91) Placebo 100 mg 300 mg 100 mg 300 mg Barst RJ et al. Am J Respir Crit Care Med. 2004;169:
36 Change in Six-Minute Walk Distance (m) STRIDE-2: Change in 6-MWD from Baseline to Week 18 Sitax 100mg * OL Bosentan ** Sitax 50mg Placebo Week * p=0.03 sitax 100mg vs. placebo p=0.07 sitax 50mg vs. placebo ** p=0.05 OL bosentan vs. placebo m ± SE Barst et al. J Am Coll Cardiol 2006;47:
37 Ambrisentan in PAH: 6-Minute Walk Distance Change from Baseline at Week 12 Change in 6MWD (meters) mg 2.5 mg 5 mg 10 mg All Doses n=16 n=19 n=16 n=13 n=64 p= p= p= p= p= Nazzareno Galié MD, David Badesch MD, Ronald Oudiz MD, Gérald Simonneau MD, Michael D. McGoon MD, Anne M. Keogh MD, Adaani E. Frost MD, Diane Zwicke MD, Robert Naeije MD, Shelley Shapiro MD, PhD, Horst Olschewski MD and Lewis J. Rubin MD. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol Aug 2;46(3):
38 Ambrisentan in PAH: Hemodynamics Week 0 (n=34) and Week 12 (n=29) mmhg dynes sec cm -5 Mean Pulmonary Artery Pressure Cardiac Index = -5.2 = p<0.001 Week 0 Week 12 L/min/m Week 0 Week 12 Pulmonary Vascular Resistance Mean Right Atrial Pressure = = p<0.001 p=ns Week 0 Week 12 Week 0 Week 12 mmhg p<0.001
39 Ambrisentan in PAH: Adverse Events 12-Week Blinded Treatment Period Peripheral Edema Upper Respiratory Tract Infection Nasal Congestion Headache Nausea Flushing LFTs >3X LFTs >8X Percent of Subjects with AE (%)
40 Ambrisentan ARIES-1 Primary Endpoint: Change in 6MWD at Week 12 Change in 6MWD (m) m m m -25 Week 0 Week 4 Week 8 Week 12 N=202. Placebo-adjusted changes: 10 mg = m (P=0.0001) 5 mg = m (P=0.0084) Oudiz RJ, et al. Chest. 2006;130:Abstract 121S. Placebo 5 mg 10 mg
41 Ambrisentan ARIES-2 Primary Endpoint: Change in 6MWD at Week 12 Mean Change in 6MWD (m) Week 0 Week 4 Week 8 Week 12 N=192. Placebo-adjusted changes: 2.5 mg = 32.3 m (P=0.022) 5 mg = 59.4 m (P<0.001) Olschewski H, et al. ATS San Diego m m m Placebo 2.5 mg 5 mg
42 ARIES-2: Time to Clinical Worsening With Ambrisentan Probability of No Clinical Worsening of PAH Placebo Ambrisentan 2.5 mg Ambrisentan 5 mg Ambrisentan combined dosages 5 mg (P=0.008) 2.5 mg (P=0.005) Week 0 Week 4 Week 8 Week & 5 mg (P <0.001) Placebo Week 16 Time to clinical worsening = Combined endpoint of death, lung transplantation, atrial septostomy, hospitalization for PAH, addition of other drugs for PAH, or early escape from clinical trial. Olschewski H, et al. ATS San Diego.
43 PAH: Advanced Therapy A) PGI 2 SMC EC PGI 2 -S Arach. a. PGI 2 camp PGI 2 Sildenafil TxA 2 SMC PDE 5 cgmp Vasodilation Antiproliferative B) NO EC L-arginine L-citrulline NO Vasoconstriction Proliferation C) ET-1 SMC G I ET A ET B EC Pre-pro-ET pro-et ET-1 Adapted from Omar Manai.
44 Sildenafil in PAH SUPER-1: Study Design Screening Randomization 4 Weeks 8 Weeks 12 Weeks Placebo tid 20 mg tid 40 mg tid 80 mg tid 6-min-walk BORG 6-min-walk BORG 6-min-walk BORG Clinical Worsening 6-min-walk BORG Clinical Worsening 6-min-walk BORG Clinical Worsening Hemodynamics Hemodynamics Galiè N et al for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. NEJM 353: ;2005.
45 Sildenafil in PAH SUPER-1: Improvements in 6-MWD Change from baseline (m) Week 4 Week 8 Week 12 *p< * * * 45 m 46 m 50 m Placebo Sildenafil 20 mg Sildenafil 40 mg Sildenafil 80 mg Galiè N et al for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. NEJM 353: ;2005.
46 Sildenafil in PAH SUPER-1: Hemodynamics Change from baseline at Week mpap (mm Hg) -2.7 p= p=0.01 p< Cardiac Output (L/min) p= p=0.03 p< PVR (dyne.s/cm 5 ) p= p=0.006 p< Week 4 Week 4 Week 4 Placebo Sildenafil 20 mg Sildenafil 40 mg Sildenafil 80 mg Galiè N et al for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. NEJM 353: ;2005.
47 Sildenafil in PAH SUPER-1: AEs 3% and Sildenafil > Placebo Percentage of patients reporting event Adverse event Sildenafil (N=207) Placebo (N=70) Headache Flushing 12 4 Dyspepsia 12 7 Back Pain Diarrhea 11 6 Limb pain 10 6 Myalgia 9 4 Cough 7 6 Epistaxis 7 1 Pyrexia 6 3 Influenza 5 3 Gastritis 3 0 Vertigo 3 1 Erythema 3 0 Galiè N et al for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. NEJM 353: ;2005.
48 Medical Therapy: Functional Class II 10. PAH patients in functional class II who are not candidates for, or who have failed, CCB therapy, may benefit from treatment with: a. Sildenafil (Level of Evidence: Good; Benefit: Substantial; Grade of Recommendation: A). b. Subcutaneous treprostinil (Level of Evidence: Low; Benefit: Small/Weak; Grade of Recommendation: C). c. IV treprostinil (Level of Evidence: Low; Benefit: Small/Weak; Grade of Recommendation: C). Although treprostinil is FDA approved for use in patients in FC II, it would seldom be recommended in such patients due to the complexity of administration, side effects, and cost. Data pertaining to the treatment of FC II patients remain limited, and enrollment in clinical trials is encouraged.
49 Symptomatic Pulmonary Arterial Hypertension ACCP 2007 General Treatment Measures: Oral anticoagulants [B for IPAH, E/C for other PAH] + diuretics + oxygen [E/A] Acute Vasoreactivity Testing [A for IPAH, E/C for other PAH] Positive Negative Oral CCB [B for IPAH, E/B for other PAH] FC II Sustained Response? Yes No Continue CCB Sildenafil [A] Treprostinil SC [C] Treprostinil IV [C] Grade of Recommendation Noted in [ ] Badesch, Abman, Simonneau,et al. Chest 131: ;131.
50 Medical Therapy: Functional Class III 11. PAH patients in functional class III who are not candidates for, or who have failed, calcium channel blocker therapy, are candidates for longterm therapy with: a. Endothelin receptor antagonists (bosentan), or sildenafil, in no order of preference. Level of Evidence: Good; Benefit: Substantial; Grade of Recommendation: A. b. IV epoprostenol. Level of Evidence: Good; Benefit: Substantial; Grade of Recommendation: A. c. Inhaled iloprost. Level of Evidence: Good; Benefit: Intermediate; Grade of Recommendation: A. d. Subcutaneous treprostinil. Level of Evidence: Fair; Benefit: Intermediate; Grade of Recommendation: B. e. IV trepostinil. Level of Evidence: Low; Benefit: Intermediate; Grade of Recommendation: C. With the approval of ambrisentan by the FDA, the recommendations for FC II and III patients will need to be updated again.
51 Symptomatic Pulmonary Arterial Hypertension ACCP 2007 General Treatment Measures: Oral anticoagulants [B for IPAH, E/C for other PAH] + diuretics + oxygen [E/A] Acute Vasoreactivity Testing [A for IPAH, E/C for other PAH] Positive Negative Oral CCB [B for IPAH, E/B for other PAH] FC II FC III Sustained Response? Yes No Continue CCB Sildenafil [A] Treprostinil SC [C] Treprostinil IV [C] Bosentan [A] Sildenafil [A] Epoprostenol [A] Iloprost inh [A] Treprostinil SC [B] Treprostinil IV [C] Grade of Recommendation Noted in [ ] Badesch, Abman, Simonneau,et al. Chest 131: ;131.
52 Medical Therapy: Functional Class IV 12. PAH patients in functional class IV who are not candidates for, or who have failed, calcium channel blocker therapy, are candidates for long-term therapy with intravenous epoprostenol (treatment of choice). Level of Evidence: Good; Benefit: Substantial; Grade of Recommendation: A. 13. Other treatments available for the treatment of functional class IV PAH patients include, in no hierarchal order: a. Endothelin receptor antagonists (bosentan). Level of Evidence: Fair; Benefit: Intermediate; Grade of Recommendation: B. b. Inhaled iloprost. Level of Evidence: Fair; Benefit: Intermediate; Grade of Recommendation: B. c. Subcutaneous treprostinil. Level of Evidence: Fair; Benefit: Intermediate; Grade of Recommendation: B. d. Sildenafil. Level of Evidence: Low; Benefit: Intermediate; Grade of Recommendation: C. e. IV treprostinil. Level of Evidence: Low; Benefit: Intermediate; Grade of Recommendation: C.
53 Symptomatic Pulmonary Arterial Hypertension ACCP 2007 General Treatment Measures: Oral anticoagulants [B for IPAH, E/C for other PAH] + diuretics + oxygen [E/A] Acute Vasoreactivity Testing [A for IPAH, E/C for other PAH] Positive Negative Oral CCB [B for IPAH, E/B for other PAH] FC II FC III FC IV Sustained Response? Yes No Continue CCB Sildenafil [A] Treprostinil SC [C] Treprostinil IV [C] Bosentan [A] Sildenafil [A] Epoprostenol [A] Iloprost inh [A] Treprostinil SC [B] Treprostinil IV [C] Epoprostenol IV [A] Bosentan [B] Iloprost inh [B] Sildenafil [C] Treprostinil SC [C] Treprostinil IV [C] Grade of Recommendation Noted in [ ] Badesch, Abman, Simonneau,et al. Chest 131: ;131.
54 STEP Study of Inhaled Iloprost in Patients Already Receiving Bosentan: Post-inhalation change in 6-MWD (Week 12) Iloprost Placebo Meters Change Meters Change Walked from Baseline Walked from Baseline Baseline (m) Mean Week 12 (m) Mean m m p-value (vs. baseline) Placebo-adjusted Difference: +26 m (p = 0.051) McLaughlin et al: In press, AJRCCM.
55 PAH Study of Sildenafil added to Background Epoprostenol Therapy Change from Baseline in 6-MWD Simonneau et al. Presented at ATS 2006.
56 Symptomatic Pulmonary Arterial Hypertension ACCP 2007 General Treatment Measures: Oral anticoagulants [B for IPAH, E/C for other PAH] + diuretics + oxygen [E/A] Acute Vasoreactivity Testing [A for IPAH, E/C for other PAH] Positive Negative Oral CCB [B for IPAH, E/B for other PAH] FC II FC III FC IV Sustained Response? Yes No Continue CCB Sildenafil [A] Treprostinil SC [C] Treprostinil IV [C] Bosentan [A] Sildenafil [A] Epoprostenol [A] Iloprost inh [A] Treprostinil SC [B] Treprostinil IV [C] Epoprostenol IV [A] Bosentan [B] Iloprost inh [B] Sildenafil [C] Treprostinil SC [C] Treprostinil IV [C] Combination Therapy? Prostanoid Bosentan Sildenafil Grade of Recommendation Noted in [ ] Badesch, Abman, Simonneau,et al. Chest 131: ;131. No Improvement or deterioration Atrioseptostomy + Lung Transplantation
57 Medical Therapy: Children and Pregnancy 15. In children with PAH, the recommendations for medical therapy (other than anticoagulation) in adults also apply. Quality of Evidence: Low; Net Benefit: Substantial; Strength of Recommendation: B. 16. a. Children with PAH with right heart failure, or with a hypercoagulable state, should be anticoagulated with warfarin. Level of Evidence: Expert Opinion; Net Benefit: Intermediate; Strength of Recommendation: E/B. b. Children with PAH without right heart failure or a hypercoagulable state, may be anticoagulated with warfarin; for children less than 5 years of age, lower target INRs are recommended. Level of Evidence: Expert Opinion; Net Benefit: Small/Weak; Strength of Recommendation: E/C. 17. In patients with PAH, pregnancy should be avoided, or termination recommended. Level of Evidence: Good; Benefit: Substantial; Grade of recommendation: A.
58 Symptomatic Pulmonary Arterial Hypertension ACCP 2007 General Treatment Measures: Oral anticoagulants [B for IPAH, E/C for other PAH] + diuretics + oxygen [E/A] Acute Vasoreactivity Testing [A for IPAH, E/C for other PAH] Positive Negative Oral CCB [B for IPAH, E/B for other PAH] FC II FC III FC IV Sustained Response? Yes No Continue CCB Sildenafil [A] Treprostinil SC [C] Treprostinil IV [C] Bosentan [A] Sildenafil [A] Epoprostenol [A] Iloprost inh [A] Treprostinil SC [B] Treprostinil IV [C] Epoprostenol IV [A] Bosentan [B] Iloprost inh [B] Sildenafil [C] Treprostinil SC [C] Treprostinil IV [C] Combination Therapy? Prostanoid Bosentan Sildenafil Grade of Recommendation Noted in [ ] Badesch, Abman, Simonneau,et al. Chest 131: ;131. No Improvement or deterioration Atrioseptostomy + Lung Transplantation
What Surgeons Need to Know About. Pulmonary Arterial Hypertension
What Surgeons Need to Know About Pulmonary Arterial Hypertension David B. Badesch, MD Professor of Medicine University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch
More informationRole of Combination PAH Therapies
Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationTherapeutic approaches in P(A)H and the new ESC Guidelines
Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium
More informationMedical Therapy for Pulmonary Arterial Hypertension* Updated ACCP Evidence-Based Clinical Practice Guidelines
CHEST Clinical Practice Guidelines Medical Therapy for Pulmonary Arterial Hypertension* Updated ACCP Evidence-Based Clinical Practice Guidelines David B. Badesch, MD, FCCP; Steven H. Abman, MD; Gerald
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationAdvances in Pharmacotherapy of PAH
24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationAmbrisentan Therapy for Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 46, No. 3, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.04.050
More informationIV PGI2 vs. Inhaled PGI2 in chronic lung disease
Inhaled Therapies for PAH Erika Berman Rosenzweig, MD Associate Professor of Clinical Pediatrics (in Medicine) Director, Pulmonary Hypertension Center Columbia University Medical Center Disclosures Has
More informationDisclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline
Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar
More informationProgress in PAH. Gerald Simonneau
Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of
More informationTherapy Update: ERAs. Review of Mechanism. Disclosure Statements. Outline. Disclosure: Research support from United Therapeutics
1 Therapy Update: ERAs Disclosure Statements Disclosure: Research support from United Therapeutics Most of the medications discussed in this presentation are off-label usage Nidhy Varghese, MD Pulmonary
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationThe Case of Marco Nazzareno Galiè, M.D.
The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More information*Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA
The Relationship between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients with PAH Not Reaching Treatment Goals with Phosphodiesterase 5 Inhibitors James R Klinger,* Raymond
More informationManaging Multiple Oral Medications
Managing Multiple Oral Medications Chris Archer-Chicko, MSN, CRNP PENN Presbyterian Medical Center Arlene Schiro,, CRNP Massachusetts General Hospital Mary Bartlett, CRNP Winthrop University Hospital PH
More informationChronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness
More informationThe US REVEAL Registry
Pulmonary Hypertension: Lessons from Contemporary Registries The US REVEAL Registry ESC August 30, 2010 Dave Badesch, MD University of Colorado Disclosures Dr. Badesch has received grant/research support
More informationBosentan for treatment of pulmonary arterial hypertension (I)
KEY PAPER EVALUATION Bosentan for treatment of pulmonary arterial hypertension (I) Sabina A Antoniu University of Medicine and Pharmacy, Clinic of Pulmonary Disease, 62 Costache Negri St, Bl.C2, Sc.A,
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationObjectives. Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease
Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease Erika Berman Rosenzweig, MD Director, Pulmonary Hypertension Center Associate Professor of Clinical Pediatrics (in Medicine)
More informationPulmonary Arterial Hypertension (PAH) Treatments
Care1st Health Plan Arizona, Inc. Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health
More informationIn focus The paediatric PAH population Clinicians Perspectives
In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire
More informationScottish Medicines Consortium
Scottish Medicines Consortium sildenafil, 20mg (as citrate) tablets (Revatio ) No. (596/10) Pfizer Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationTadalafil for the Treatment of Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 60, No. 8, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.004
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationTreatment of Paediatric Pulmonary Hypertension
Treatment of Paediatric Pulmonary Hypertension Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine 1 Disclosures I have the following financial relationships
More informationUpdates on Pulmonary Hypertension Treatment
Updates on Pulmonary Hypertension Treatment Dane Mellgren, PharmD PGY-1 Pharmacy Practice Resident Hennepin County Medical Center 04/27/18 Disclosure I have no disclosures to be made regarding the content
More information(CHEST 2004; 126:35S 62S)
Medical Therapy For Pulmonary Arterial Hypertension* ACCP Evidence-Based Clinical Practice Guidelines David B. Badesch, MD, FCCP; Steve H. Abman, MD; Gregory S. Ahearn, MD; Robyn J. Barst, MD; Douglas
More informationUntreated idiopathic pulmonary arterial hypertension
Congenital Heart Disease Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension Delphine Yung, MD; Allison C. Widlitz, MS, PA; Erika Berman Rosenzweig, MD; Diane Kerstein, MD; Greg Maislin,
More informationClass Update with New Drug Evaluation: Drugs for Pulmonary Arterial Hypertension
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationΠνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ
Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ PH is defined as PAPm 25 mm Hg at rest The general definition of PH remains unchanged Most of the relevant epidemiological and therapeutic studies have used the 25 mm
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationTeaching Round Claudio Sartori
Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2
More informationEffects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 46, No. 4, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.066
More informationPulmonary Hypertension Drugs
Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/22/2015 Section: Prescription Drugs
More informationPulmonary Hypertension Drugs
Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 05/25/2012 Section: Prescription Drugs Place(s) of Service:
More information4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology
Pulmonary Hypertension: An Update Tim Williamson, MD, FCCP Director, Pulmonary Vascular Program University of Kansas Hospital Normal Physiology 1 Pulmonary Perfusion 101 High Pressure Low Pressure Pulmonary
More informationTreprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan
CHEST Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan Raymond L. Benza, MD; Barry K. Rayburn, MD; Jose
More informationPulmonary Arterial Hypertension: The Approach to Management in 2019
Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationLong-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
Eur Respir Rev 2009; 18: 114, 253 259 DOI: 10.1183/09059180.00003109 CopyrightßERSJ Ltd 2009 REVIEW Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
More informationRaymond L. Benza, MD, a Mardi Gomberg-Maitland, MD, MSc, b Robert Naeije, MD, PhD, c Carl P. Arneson, MStat, d and Irene M.
http://www.jhltonline.org Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled
More informationΠνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION. Αναστασία Ανθη
Πανελλήνια Σεμινάρια Ομάδων Εργασίας 2017 k Πνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION Αναστασία Ανθη Β Κλιν. Εντατικής Θεραπείας & Διακλινικό Ιατρείο Πνευμ. Υπέρτασης Π.Γ.Ν.
More informationDoes Tadalafil Improve Exercise Capacitance in Patients over 12 Years Old with Pulmonary Hypertension?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Does Tadalafil Improve Exercise Capacitance
More informationUpdates in Pulmonary Hypertension Pharmacotherapy. Ziad Sadik PharmD BCPS
Updates in Pulmonary Hypertension Pharmacotherapy Ziad Sadik PharmD BCPS Disclosure Information I have no financial relationship to disclose AND I will not discuss off label use and/or investigational
More informationClinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88
Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationLong-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 54, No. 21, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.07.033
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 10/1/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationIntravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Eur Respir J 2002; 20: 339 343 DOI: 10.1183/09031936.02.02462001 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Intravenous iloprost for
More informationThe need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension
REVIEW 6MWD IN PAH TRIALS The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension Sean Gaine 1 and Gérald Simonneau 2 Affiliations: 1 National Pulmonary Hypertension
More informationCONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION
CONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION MOHAMMED RAFIQUE ESSOP MILPARK HOSPITAL and UNIVERSITY OF THE WITWATERSRAND POINTS FOR DISCUSSION What is the pathogenetic mechanism of PAH? Importance of
More informationSTARTS-1 and -2. Barst R, Ivy DD, et al. Circulation 2012;125:
STARTS-1 and -2 A randomized, double-blind,16 week placebo controlled, dose ranging, parallel group study of oral monotherapy sildenafil in treatment naive children, aged 1-17 years, with pulmonary arterial
More information2012 CADTH Symposium. April 2012
2012 CADTH Symposium Using Mixed Treatment Comparisons to compare Oral Treatments for Pulmonary Arterial Hypertension and Inform Policy Decisions by a Public Drug Plan April 2012 Objective of this Presentation
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationCombination therapy in the treatment of pulmonary arterial hypertension 2015 update
Journal of Rare Cardiovascular Diseases 2015; 2 (4): 103 107 www.jrcd.eu REVIEW ARTICLE Rare diseases of pulmonary circulation Combination therapy in the treatment of pulmonary arterial hypertension 2015
More informationSurvival in patients with pulmonary arterial hypertension treated with first-line bosentan
European Journal of Clinical Investigation (2006) 36 (Suppl. 3), 10 15 Blackwell Publishing Ltd Survival in patients with pulmonary arterial hypertension treated with first-line bosentan V. V. McLaughlin
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationAddition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy
Addition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy Wouter Jacobs, MD, a Anco Boonstra, MD, PhD, a J. Tim Marcus, PhD, b Pieter E. Postmus, MD, PhD, a and Anton Vonk-Noordegraaf,
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationCurrent and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06
Current and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06 Pulmonary Hypertension A mean pressure of greater than 25 mm Hg at rest (normal ~14 mm Hg) or greater
More informationPulmonary Hypertension - Current Perspectives. Dr. Dipesh Maskey Dept of Pulmonology and CCM PGIMER,CHD 29/01/2010
Pulmonary Hypertension - Current Perspectives Dr. Dipesh Maskey Dept of Pulmonology and CCM PGIMER,CHD 29/01/2010 Pulmonary Hypertension Characterized by Restricted flow through the pulmonary arterial
More informationPulmonary Hypertension: Evolution and
Management of Pulmonary Hypertension: Evolution and Controversies VERMONT CARDIAC NETWORK SPRING CONFERENCE MAY 10, 2018 MARYELLEN ANTKOWIAK, MD, PULMONARY & CRITICAL CARE MEDICINE, UVMMC WHO classification
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationSelection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort
Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort Robert Schilz, DO, PhD, FCCP Medical Director, Lung Transplantation and Pulmonary Vascular Disease
More informationSildenafil for Pulmonary Arterial Hypertension Associated with Connective Tissue Disease
Sildenafil for Pulmonary Arterial Hypertension Associated with Connective Tissue Disease DAVID B. BADESCH, NICHOLAS S. HILL, GARY BURGESS, LEWIS J. RUBIN, ROBYN J. BARST, NAZZARENO GALIÈ, and GERALD SIMONNEAU,
More informationIntravenous Therapies for Pulmonary Hypertensive Vascular Disease. Intravenous Treatment for PAH: Past, Present and Future 3/10/2012
Intravenous Therapies for Pulmonary Hypertensive Vascular Disease Robyn J Barst MD Professor Emeritus Columbia University New York, NY March 1 th 212 Presented By: Erika Berman Rosenzweig, MD Dr. Robyn
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationProstacyclin has potent vasodilatory,
Eur Respir Rev 29; 18: 111, 29 34 DOI: 1.1183/95918.11111 CopyrightßERSJ Ltd 29 Inhaled iloprost for the treatment of pulmonary hypertension H. Olschewski ABSTRACT: Prostacyclin and its analogues (prostanoids)
More information22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment
22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School
More informationAdvanced Therapies for Pharmocological Treatment of Pulmonary Arterial Hypertension. Original Policy Date
MP 5.01.07 Advanced Therapies for Pharmocological Treatment of Pulmonary Arterial Hypertension Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationPulmonary Arterial Hypertension Drug Prior Authorization Protocol
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION Macitentan (Opsumit Actelion Pharmaceuticals Canada Inc.) Indication: Pulmonary Arterial Hypertension Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that
More informationApproach to Pulmonary Hypertension in the Hospital
Approach to Pulmonary Hypertension in the Hospital Todd M Bull MD Professor of Medicine Director Pulmonary Vascular Disease Center Director Center for Lungs and Breathing Division of Pulmonary Sciences
More informationLong-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension
CHEST Original Research PULMONARY VASCULAR DISEASE Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension The SUPER-2 Study Lewis J. Rubin, MD, FCCP ; David B. Badesch, MD, FCCP
More informationContreversies in the management of PH What is controversial in treatment?
Contreversies in the management of PH What is controversial in treatment? Service de Pneumologie et Réanimation National reference center for pulmonary hypertension Université Paris Sud Hôpital Antoine
More informationSalvatore Rosanio, 1 Francesco Pelliccia, 2 Carlo Gaudio, 2 Cesare Greco, 2 Abdul M. Keylani, 1 and Darrin C. D Agostino 1. 1.
BioMed Research International, Article ID 743868, 17 pages http://dx.doi.org/10.1155/2014/743868 Review Article Pulmonary Arterial Hypertension in Adults: Novel Drugs and Catheter Ablation Techniques Show
More informationUpdate on the Management of Pulmonary Hypertension
Update on the Management of Pulmonary Hypertension Weston Bush, PharmD, BCPS Clinical Pharmacy Specialist, SICU University Hospitals Case Medical Center Disclosures None Treatment (Conventional/Supportive)
More informationOverview of current therapeutic approaches for pulmonary hypertension
Review Article Overview of current therapeutic approaches for pulmonary hypertension Jason A. Stamm 1, Michael G. Risbano 2, and Michael A. Mathier 3 1 Department of Pulmonary, Allergy, and Critical Care
More informationSATELLITE SYMPOSIUM OF MSD. sgc Stimulation for the treatment of PH. Real life management of PAH: case presentation
SATELLITE SYMPOSIUM OF MSD sgc Stimulation for the treatment of PH Real life management of PAH: case presentation Eftychia Demerouti MD, MSc, PhD Cardiologist Onassis Cardiac Surgery Center Conflict of
More informationClinical Commissioning Policy: Selexipag for treating pulmonary arterial hypertension (all ages)
Clinical Commissioning Policy: Selexipag for treating pulmonary arterial hypertension (all ages) NHS England Reference: 170065P 1 NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationWhere are we now in the longterm. of PAH and CTEPH? Hits and misses of medical treatment. Hap Farber Boston University School of Medicine, Boston, USA
Where are we now in the longterm management of PAH and CTEPH? Hits and misses of medical treatment Hap Farber Boston University School of Medicine, Boston, USA Monday, 28 September ERS International Congress
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More informationPulmonary hypertension; does gender matter?
Pulmonary hypertension; does gender matter? Nazzareno Galiè Istituto di Cardiologia Università di Bologna nazzareno.galie@unibo.it Galiè N et al. European Heart Journal (2009) 30, 2493 2537 Pulmonary Hypertension
More informationUpdated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 54, No. 1, Suppl S, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.04.017
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More information